Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Graham Osborn who wrote (60762)	5/1/2018 11:01:04 AM
From: Micah Lance	Respond to of 78795

Graham, I had a longer message typed out and deleted bc of the news posted below. Let me dig further here. I have been bearish on the praluent launch, but then I saw this today: "A rare ceasefire has been declared in the battle over the nation’s drug prices. Express Scripts Holding Co., one of the biggest U.S. pharmacy-benefit managers, agreed to ease restrictions on a novel cholesterol-cutting therapy after its manufacturers, Regeneron Pharmaceuticals Inc. and Sanofi, lowered its $14,600-a-year price. The deal is the first struck since the March announcement by Regeneron and Sanofi that they would cut the price of their drug, Praluent, in exchange for better access to patients." Previously, insurers wouldn't cover praluent due to pricing, but this could provide some nice upside if praluent sales start picking up. I'd like to see what their pipeline looks like first, I'll message back when I have some more in-depth thoughts.